Cargando…
New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting gluc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Higher Education Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883012/ https://www.ncbi.nlm.nih.gov/pubmed/35226299 http://dx.doi.org/10.1007/s11684-021-0873-2 |